Boston – Cooley advised the underwriters on Minerva Neurosciences' $32.7 million IPO. Minerva is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company now trades on the Nasdaq Global Stock Market under the symbol "NERV."
Jefferies acted as sole book-running manager for the offering and Baird and JMP Securities acted as co-managers.
Thus far in 2014, Cooley has advised on 65 completed public offerings, including 32 completed IPOs.